Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

Angeles, California; founder and director-emeritus of The New England Center for Headache; and clinical investigator for the Phase II study.

Merck continues to anticipate filing a New Drug Application (NDA) for MK-0974 with the U.S. Food and Drug Administration in 2009.

About migraines

Migraine headaches impact approximately 28 million Americans, primarily women. Unlike a bad headache, migraines are characterized by attacks of intense, usually one-sided, throbbing head pain that can last from four to 72 hours. The pain associated with migraine is frequently accompanied by other associated symptoms, including nausea, vomiting and increased sensitivity to light and/or sound.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new i
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:9/23/2014)... 2014 According to the ... (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application (General ... Global Forecasts to 2019", published by MarketsandMarkets, studies the ... of 2014 to 2019. The market is expected ... of 9.6% from 2014 to 2019. ...
(Date:9/23/2014)... Ill. , Sept. 23, 2014  Medela announced ... Atlanta Biomedical Company (ABC), assigning Medela as the exclusive ... now known as the Medela Enteral Feeding Pump. Through ... to help NICU parents and healthcare professionals by offering ... The Medela Enteral Feeding Pump is integral to the ...
(Date:9/23/2014)... , Sept. 23, 2014 A case report ... a SynCardia temporary Total Artificial Heart into a patient ... ventricles were reversed, along with other abnormalities. ... modifying the SynCardia Total Artificial Heart to treat a ... report and video in the Journal of Visualized Experiments ...
Breaking Medicine Technology:Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4
... 10, 2011 In the year since a devastating earthquake ... and around the world have launched and supported projects to ... the New Year began, Rotary clubs started a $200,000 initiative ... outbreak of the waterborne disease. Rotary clubs worldwide ...
... Jan. 10, 2011 CoreLab Partners, Inc , ... Inc and Medifacts International, has launched a new advanced ... are pleased to announce the release of our proprietary ... development continuum by offering sponsors advanced technologies and integrated ...
Cached Medicine Technology:Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 2Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 3CoreLab Partners Launches Advanced Imaging Application 2CoreLab Partners Launches Advanced Imaging Application 3
(Date:9/23/2014)... Ore. A recent Oregon survey about an exercise ... the daily routine of elementary school students found it ... and teachers, and offered clear advantages for overly sedentary ... developed and produced by the Healthy Youth Program of ... is available nationally. , Brain Breaks leads children in ...
(Date:9/23/2014)... national report showing the benefits of preventing a ... Medicaid services was released today by the American ... Congress Must Save the Medicaid Primary Care Pay ... Access to Life-Saving Primary Care Will Expire," explains ... access to internists and pediatricians (and their related ...
(Date:9/23/2014)... Vancouver Electrician Contractors, Pro Ace, has recently announced ... in Vancouver, BC. The company will provide services on ... maintenance project or a large-scale new installation project, Pro ... needs of the individual commercial client. Pro Ace has ... affordable price. As a result, businesses of all sizes ...
(Date:9/23/2014)... September 23, 2014 The ... rhinitis (AR) is highly fragmented, with the ... formulations available, under different regulatory restrictions, with ... Europe has the most developed market, with ... allergen immunotherapy tablets (AITs) all being available. ...
(Date:9/23/2014)... SOURCE: Solutions from Our Country’s Entrepreneurs ... Rimidi Diabetes and TruClinic (TM) ... to challenges faced by patients and healthcare systems. ... The Hitachi Foundation, Village Capital, and ... investment capital, mentoring, and support needed to grow their ...
Breaking Medicine News(10 mins):Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5
... ... Island man,s sense of smell and taste , ... Mineola, N.Y.(Lexis Nexis) July 8, 2009 -- Marc Grossman , senior ... N.Y., today announced that his firm has filed a civil lawsuit against the manufacturer of ...
... -- Perot Systems Corporation (NYSE: PER ) ... a Chinese-language website as part of the company,s expanded presence ... , , "Perot Systems is in the early stages ... for the reception we have received from local leaders across ...
... Chairman of the U.S. Catholic Bishops, Committee on Pro-Life ... stem cell research issued yesterday by the National Institutes ... , , "In April I criticized the NIH,s ... that under these guidelines ,federal tax dollars will be ...
... -- Chemical dependency and recovery in patients and physicians ... editorials in the July 2009 issue of Mayo ... the immense challenges, including potential tragedies, of prescription chemical ... crucial overview, direction and optimism. Addiction to ...
... July 7 DRINKiQ.com , Diageo,s ... Communicator Award as the Most Outstanding Health and Wellness web ... The site was also named runner-up in the Education Category. ... honors creative excellence for communications professionals. The program is sanctioned ...
... 7 AMB Property Corporation(R) (NYSE: AMB ), ... today announced that it has fully leased a 328,000 square ... in Hamburg to BSN medical GmbH, a leading global medical ... BSN medical,s previous commitment to 210,000 square feet (19,500 square ...
Cached Medicine News:Health News:New York Law Firm Files Lawsuit Against Manufacturer of Zicam Nasal Spray and Drugstore Chain That Sold Product 2Health News:Perot Systems Launches Website in Chinese to Support Expansion Into China 2Health News:Cardinal Rigali Criticizes Final NIH Guidelines for Destructive Stem Cell Research 2Health News:A comprehensive review of addiction to prescription painkillers among patients and physicians 2Health News:A comprehensive review of addiction to prescription painkillers among patients and physicians 3Health News:Diageo's DRINKiQ.com Honored as Most Outstanding Health & Wellness Site by International Academy of the Visual Arts 2Health News:Diageo's DRINKiQ.com Honored as Most Outstanding Health & Wellness Site by International Academy of the Visual Arts 3Health News:AMB Property Corporation(R) Leases 440,000 SF in Hamburg 2Health News:AMB Property Corporation(R) Leases 440,000 SF in Hamburg 3Health News:AMB Property Corporation(R) Leases 440,000 SF in Hamburg 4
... Verisyse Phakic IOL is used to ... medical term for nearsightedness. With over ... procedures performed worldwide, results prove that ... effective for very nearsighted people who ...
... CELL-DYN 3200 sets a benchmark of ... scatter for WBC, RBC, PLT and ... the needs of today's laboratory. The ... differential analysis, automated sample handling, comprehensive ...
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
Inquire...
Medicine Products: